FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136179143> ?p ?o ?g. }

• W3136179143 endingPage "3078" @default.
• W3136179143 startingPage "3069" @default.
• W3136179143 abstract "Capecitabine plus oxaliplatin (CAPOX) is one of the standard first-line treatments for unresectable, advanced, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Camrelizumab shows promising antitumor activity in advanced or metastatic G/GEJ adenocarcinoma in a phase I study. We reported the outcomes of cohort 1 in a multicenter, open-label, phase II trial, which assessed camrelizumab in combination with CAPOX followed by camrelizumab plus apatinib as a first-line combination regimen for advanced or metastatic G/GEJ adenocarcinoma.Systemic treatment-naïve patients with EGFR2-negative advanced or metastatic G/GEJ adenocarcinoma received initial camrelizumab plus CAPOX for 4-6 cycles, and patients without progressive disease were administrated subsequent camrelizumab plus apatinib. Primary endpoint was objective response rate (ORR).All 48 enrolled patients comprised the efficacy and safety analysis population. The ORR was 58.3% [95% confidence interval (CI), 43.2-72.4] with this combination regimen. Median duration of response was 5.7 months (95% CI, 4.4-8.3). Median overall survival was 14.9 months (95% CI, 13.0-18.6), and median progression-free survival was 6.8 months (95% CI, 5.6-9.5), respectively. The most common grade ≥3 treatment-related adverse events (>10%) were decreased platelet count (20.8%), decreased neutrophil count (18.8%), and hypertension (14.6%). Treatment-related death occurred in 1 patient (2.1%) due to abnormal hepatic function and interstitial lung disease.Camrelizumab combined with CAPOX followed by camrelizumab plus apatinib demonstrated encouraging antitumor activity and manageable toxicity as first-line therapy for patients with advanced or metastatic G/GEJ adenocarcinoma." @default.
• W3136179143 created "2021-03-29" @default.
• W3136179143 creator A5012853410 @default.
• W3136179143 creator A5025574128 @default.
• W3136179143 creator A5038853266 @default.
• W3136179143 creator A5039152336 @default.
• W3136179143 creator A5044825014 @default.
• W3136179143 creator A5045723123 @default.
• W3136179143 creator A5048541371 @default.
• W3136179143 creator A5055316048 @default.
• W3136179143 creator A5057704753 @default.
• W3136179143 creator A5059392900 @default.
• W3136179143 creator A5072668135 @default.
• W3136179143 creator A5075350471 @default.
• W3136179143 creator A5078323948 @default.
• W3136179143 creator A5078989023 @default.
• W3136179143 date "2021-03-25" @default.
• W3136179143 modified "2023-10-03" @default.
• W3136179143 title "Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma" @default.
• W3136179143 cites W1518184777 @default.
• W3136179143 cites W1757407923 @default.
• W3136179143 cites W1976841472 @default.
• W3136179143 cites W2022609714 @default.
• W3136179143 cites W2104709039 @default.
• W3136179143 cites W2108661938 @default.
• W3136179143 cites W2122866527 @default.
• W3136179143 cites W2127773543 @default.
• W3136179143 cites W2128328462 @default.
• W3136179143 cites W2131972171 @default.
• W3136179143 cites W2154670252 @default.
• W3136179143 cites W2276228008 @default.
• W3136179143 cites W2508623887 @default.
• W3136179143 cites W2605792367 @default.
• W3136179143 cites W2725487442 @default.
• W3136179143 cites W2755320026 @default.
• W3136179143 cites W2763064222 @default.
• W3136179143 cites W2765943070 @default.
• W3136179143 cites W2789258259 @default.
• W3136179143 cites W2793364080 @default.
• W3136179143 cites W2803002566 @default.
• W3136179143 cites W2890100090 @default.
• W3136179143 cites W2896327236 @default.
• W3136179143 cites W2897612290 @default.
• W3136179143 cites W2903527992 @default.
• W3136179143 cites W2906436263 @default.
• W3136179143 cites W2906932524 @default.
• W3136179143 cites W2912403850 @default.
• W3136179143 cites W2912776918 @default.
• W3136179143 cites W2923967990 @default.
• W3136179143 cites W2934520391 @default.
• W3136179143 cites W2958083922 @default.
• W3136179143 cites W2968968778 @default.
• W3136179143 cites W3008514541 @default.
• W3136179143 cites W3010364641 @default.
• W3136179143 cites W3020689019 @default.
• W3136179143 cites W3036255811 @default.
• W3136179143 cites W3036571927 @default.
• W3136179143 cites W3082736986 @default.
• W3136179143 cites W3088611248 @default.
• W3136179143 cites W3106019786 @default.
• W3136179143 cites W3107413524 @default.
• W3136179143 cites W3111767567 @default.
• W3136179143 doi "https://doi.org/10.1158/1078-0432.ccr-20-4691" @default.
• W3136179143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33766817" @default.
• W3136179143 hasPublicationYear "2021" @default.
• W3136179143 type Work @default.
• W3136179143 sameAs 3136179143 @default.
• W3136179143 citedByCount "48" @default.
• W3136179143 countsByYear W31361791432021 @default.
• W3136179143 countsByYear W31361791432022 @default.
• W3136179143 countsByYear W31361791432023 @default.
• W3136179143 crossrefType "journal-article" @default.
• W3136179143 hasAuthorship W3136179143A5012853410 @default.
• W3136179143 hasAuthorship W3136179143A5025574128 @default.
• W3136179143 hasAuthorship W3136179143A5038853266 @default.
• W3136179143 hasAuthorship W3136179143A5039152336 @default.
• W3136179143 hasAuthorship W3136179143A5044825014 @default.
• W3136179143 hasAuthorship W3136179143A5045723123 @default.
• W3136179143 hasAuthorship W3136179143A5048541371 @default.
• W3136179143 hasAuthorship W3136179143A5055316048 @default.
• W3136179143 hasAuthorship W3136179143A5057704753 @default.
• W3136179143 hasAuthorship W3136179143A5059392900 @default.
• W3136179143 hasAuthorship W3136179143A5072668135 @default.
• W3136179143 hasAuthorship W3136179143A5075350471 @default.
• W3136179143 hasAuthorship W3136179143A5078323948 @default.
• W3136179143 hasAuthorship W3136179143A5078989023 @default.
• W3136179143 hasBestOaLocation W31361791431 @default.
• W3136179143 hasConcept C121608353 @default.
• W3136179143 hasConcept C126322002 @default.
• W3136179143 hasConcept C141071460 @default.
• W3136179143 hasConcept C143998085 @default.
• W3136179143 hasConcept C168563851 @default.
• W3136179143 hasConcept C197934379 @default.
• W3136179143 hasConcept C203092338 @default.
• W3136179143 hasConcept C2776694085 @default.
• W3136179143 hasConcept C2780668389 @default.
• W3136179143 hasConcept C2780739268 @default.
• W3136179143 hasConcept C2780962732 @default.

• next